Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 19/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17858897 | 1.00 | ESR1 (0.56) | ESR1CYP3A4KCNH2KIF11 | |
| SCHEMBL20193820 | 0.92 | ESR1 (0.62) | ESR1CYP3A4KCNH2 | |
| SCHEMBL17858935 | 0.91 | ESR1 (0.67) | ESR1CYP3A4KCNH2 | |
| SCHEMBL23722472 | 0.91 | ESR1 (0.57) | ESR1CYP3A4KCNH2 | |
| SCHEMBL22213701 | 0.91 | ESR1 (0.57) | ESR1CYP3A4KCNH2 | |
| SCHEMBL23722697 | 0.91 | ESR1 (0.57) | ESR1CYP3A4KCNH2 | |
| SCHEMBL22213758 | 0.89 | ESR1 (0.51) | ESR1CYP3A4KCNH2KIF11 | |
| SCHEMBL22213700 | 0.86 | ESR1 (0.65) | ESR1CYP3A4KCNH2 | |
| SCHEMBL22213732 | 0.86 | ESR1 (0.60) | ESR1CYP3A4KCNH2KIF11 | |
| SCHEMBL23794112 | 0.85 | ESR1 (0.74) | ESR1CYP3A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10966963-B2 | Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| EP-3760623-A1 | TETRAHYDRO-PYRIDO[3,4-B]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2021-01-06 | — | — | EP | disclosed |
| EP-3233852-B1 | TETRAHYDRO-PYRIDO[3,4-B]INDOLES AS ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2020-07-15 | — | — | EP | disclosed |
| US-9980947-B2 | Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2018-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10966963-B2 | Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof | ESR2, GPER1, ESR1 | ESR1 3/4885CYP3A4 162/4885KCNH2 4144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.